AI Engines For more Details: Perplexity Kagi Labs You
Pain Relief: Etofenamate works by inhibiting the production of prostaglandins, which are chemicals in the body that contribute to pain and inflammation. By reducing prostaglandin levels, etofenamate helps to alleviate pain associated with conditions such as muscle strains, sprains, arthritis, and other musculoskeletal injuries.
Anti-inflammatory Action: In addition to its analgesic effects, etofenamate exhibits anti-inflammatory properties by decreasing inflammation in affected tissues. This can help reduce swelling, redness, and stiffness associated with inflammatory conditions like arthritis and tendonitis.
Topical Application: Etofenamate is often applied topically to the affected area, allowing for targeted delivery of the medication to the site of pain or inflammation. Topical formulations of etofenamate are generally well-tolerated and can provide localized relief without the systemic side effects associated with oral NSAIDs.
Musculoskeletal Conditions: Etofenamate is commonly used to relieve pain and inflammation associated with various musculoskeletal conditions, including osteoarthritis, rheumatoid arthritis, tendonitis, bursitis, and other joint or soft tissue disorders.
Sports Injuries: Etofenamate is frequently used in the management of sports-related injuries such as muscle strains, ligament sprains, and overuse injuries. Its analgesic and anti-inflammatory effects can help athletes recover more quickly and return to physical activity.
Postoperative Pain: Etofenamate may be prescribed to manage postoperative pain following surgical procedures, particularly those involving the musculoskeletal system. By reducing pain and inflammation, etofenamate can improve postoperative comfort and facilitate rehabilitation.
Side Effects: Like other NSAIDs, etofenamate may cause side effects, especially with prolonged or excessive use. Common side effects may include skin irritation or rash at the site of application, burning or stinging sensation, and allergic reactions. Systemic side effects such as gastrointestinal upset, ulcers, and kidney dysfunction are rare with topical use but may occur with oral NSAIDs.
Precautions: Etofenamate should be used with caution in individuals with a history of NSAID hypersensitivity or allergic reactions. It should not be applied to broken or damaged skin or mucous membranes. Patients should avoid contact with eyes and mucous membranes and wash their hands thoroughly after application to prevent accidental ingestion or contact with sensitive areas.
Drug Interactions: Etofenamate may interact with other medications, including oral NSAIDs, anticoagulants, and corticosteroids. Patients should inform their healthcare provider about all medications they are taking to avoid potential interactions.
Special Populations: Etofenamate should be used with caution in certain populations, including pregnant or breastfeeding women, elderly individuals, and those with renal or hepatic impairment. Dosing adjustments may be necessary based on individual patient characteristics and medical history.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.6 | 0.6 | 0 |
| ADHD | 3.7 | 0.6 | 5.17 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.3 | 1.2 | 0.92 |
| Allergies | 4.5 | 3.3 | 0.36 |
| Allergy to milk products | 1.6 | 1 | 0.6 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 4.6 | 5.1 | -0.11 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.7 | 0.5 | 4.4 |
| Ankylosing spondylitis | 3.4 | 1.3 | 1.62 |
| Anorexia Nervosa | 1.4 | 2.6 | -0.86 |
| Antiphospholipid syndrome (APS) | 1.3 | 0.3 | 3.33 |
| Asthma | 3.9 | 2.1 | 0.86 |
| Atherosclerosis | 1.7 | 2.5 | -0.47 |
| Atrial fibrillation | 3.5 | 1.9 | 0.84 |
| Autism | 8.3 | 7.9 | 0.05 |
| Autoimmune Disease | 0.3 | 1 | -2.33 |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.7 | 0.7 | |
| Bipolar Disorder | 1.5 | 1.4 | 0.07 |
| Brain Trauma | 0.6 | 1.4 | -1.33 |
| Breast Cancer | 0.6 | 0.3 | 1 |
| Cancer (General) | 0.6 | 2 | -2.33 |
| Carcinoma | 2.9 | 2.6 | 0.12 |
| Celiac Disease | 2.5 | 3.7 | -0.48 |
| Cerebral Palsy | 1.2 | 1.3 | -0.08 |
| Chronic Fatigue Syndrome | 3.9 | 5.7 | -0.46 |
| Chronic Kidney Disease | 3.5 | 2.1 | 0.67 |
| Chronic Lyme | 0.3 | 0.8 | -1.67 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 1.4 | -1.33 |
| Chronic Urticaria (Hives) | 0.5 | 1.3 | -1.6 |
| Coagulation / Micro clot triggering bacteria | 0.4 | 1 | -1.5 |
| Cognitive Function | 3.3 | 1.3 | 1.54 |
| Colorectal Cancer | 5.8 | 1.9 | 2.05 |
| Constipation | 1.3 | 0.9 | 0.44 |
| Coronary artery disease | 1 | 2.4 | -1.4 |
| COVID-19 | 6.7 | 9.9 | -0.48 |
| Crohn's Disease | 6.3 | 5 | 0.26 |
| Cushing's Syndrome (hypercortisolism) | 0.7 | -0.7 | |
| cystic fibrosis | 1.7 | -1.7 | |
| deep vein thrombosis | 1.9 | 1.1 | 0.73 |
| Denture Wearers Oral Shifts | 0.4 | 0.4 | |
| Depression | 8.7 | 7.4 | 0.18 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 0.9 | 1.5 | -0.67 |
| Endometriosis | 2 | 2 | 0 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 1.9 | 2 | -0.05 |
| erectile dysfunction | 1 | 0.3 | 2.33 |
| Fibromyalgia | 2.9 | 2.1 | 0.38 |
| Functional constipation / chronic idiopathic constipation | 5 | 4.6 | 0.09 |
| gallstone disease (gsd) | 2.9 | 0.9 | 2.22 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 0.9 | 0.33 |
| Generalized anxiety disorder | 1.2 | 2.1 | -0.75 |
| giant cell arteritis | 0.2 | -0.2 | |
| Gout | 1.9 | 0.9 | 1.11 |
| Graves' disease | 1.9 | 3 | -0.58 |
| Gulf War Syndrome | 0.6 | 1.7 | -1.83 |
| Halitosis | 0.6 | 0.6 | |
| Hashimoto's thyroiditis | 3.4 | 1.6 | 1.13 |
| Heart Failure | 2.6 | 1.4 | 0.86 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 1 | 0.6 | 0.67 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.2 | 1.5 |
| hyperglycemia | 1 | 1.4 | -0.4 |
| Hyperlipidemia (High Blood Fats) | 1 | 0.3 | 2.33 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 3.8 | 5 | -0.32 |
| Hypothyroidism | 0.1 | 0.7 | -6 |
| Hypoxia | 2.1 | 0.9 | 1.33 |
| IgA nephropathy (IgAN) | 1 | 4.5 | -3.5 |
| Inflammatory Bowel Disease | 5.1 | 8 | -0.57 |
| Insomnia | 1.6 | 2.1 | -0.31 |
| Intelligence | 0.8 | 0.6 | 0.33 |
| Intracranial aneurysms | 1.2 | 0.9 | 0.33 |
| Irritable Bowel Syndrome | 6.1 | 4.5 | 0.36 |
| ischemic stroke | 2.2 | 0.8 | 1.75 |
| Liver Cirrhosis | 5 | 3.9 | 0.28 |
| Long COVID | 5.8 | 7.4 | -0.28 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.9 | 1.2 | -0.33 |
| Mast Cell Issues / mastitis | 0.9 | -0.9 | |
| ME/CFS with IBS | 0.9 | 2 | -1.22 |
| ME/CFS without IBS | 0.6 | 2 | -2.33 |
| Menopause | 1.5 | 0.6 | 1.5 |
| Metabolic Syndrome | 5.8 | 6.4 | -0.1 |
| Mood Disorders | 8.5 | 5.5 | 0.55 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.1 | 3 |
| Multiple Sclerosis | 3.7 | 5.1 | -0.38 |
| Multiple system atrophy (MSA) | 0.3 | 0.7 | -1.33 |
| myasthenia gravis | 0.7 | -0.7 | |
| neuropathic pain | 2.6 | -2.6 | |
| Neuropathy (all types) | 0.2 | 1.8 | -8 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.2 | 4.2 | 0 |
| NonCeliac Gluten Sensitivity | 1.2 | 0.6 | 1 |
| Obesity | 9.1 | 6.7 | 0.36 |
| obsessive-compulsive disorder | 4.4 | 3.4 | 0.29 |
| Osteoarthritis | 1.2 | 1 | 0.2 |
| Osteoporosis | 1.6 | 1.2 | 0.33 |
| pancreatic cancer | 0.3 | 0.3 | |
| Parkinson's Disease | 6.4 | 5.4 | 0.19 |
| Polycystic ovary syndrome | 6.2 | 3 | 1.07 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 0.9 | 0.6 | 0.5 |
| Primary sclerosing cholangitis | 1.6 | 3 | -0.88 |
| Psoriasis | 2.3 | 2.9 | -0.26 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.3 | 3.8 | 0.66 |
| Rosacea | 0.9 | 1 | -0.11 |
| Schizophrenia | 5.1 | 3.1 | 0.65 |
| scoliosis | 0.3 | 1 | -2.33 |
| Sjögren syndrome | 2.2 | 2.2 | 0 |
| Sleep Apnea | 1.9 | 1.6 | 0.19 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 0.4 | 1.75 |
| Stress / posttraumatic stress disorder | 2.4 | 2.3 | 0.04 |
| Systemic Lupus Erythematosus | 3.2 | 2 | 0.6 |
| Tic Disorder | 1 | 1.8 | -0.8 |
| Tourette syndrome | 0.7 | 0.3 | 1.33 |
| Type 1 Diabetes | 3.5 | 3.5 | 0 |
| Type 2 Diabetes | 7 | 6.3 | 0.11 |
| Ulcerative colitis | 4.2 | 6.3 | -0.5 |
| Unhealthy Ageing | 4.4 | 1.9 | 1.32 |
| Vitiligo | 2.2 | 1.6 | 0.38 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
